Key facts, as of
As of October 8, 2026, Zoetis Inc. (ZTS) trades at $71.55, down 49.9% over the past year. Its 52-week range runs from $68.77 to $148.30; the price is 51.8% below that high. It is 71.3% below its all-time high of $249.27, reached in December 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +46.6%, against +312.9% for the S&P 500 (SPY). It sits 26.7% below its 200-day average of $97.58, the usual sign of a long-term downtrend. Its 30-day volatility is 19.0% annualized, which we rate medium risk. It has a trailing P/E of 11.8 and a dividend yield of 2.96%.
Cite: Portfolio Terminal, "Zoetis Inc. (ZTS) stock analysis", 2026-10-08. https://portfolio-terminal.com/analyse/zts
Where it trades today
trading 3% of the way up its 52-week range
How the price has moved
How far it is from its record
Zoetis Inc. (ZTS) is 71.3% below its all-time high of $249.27, reached in December 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +46.6%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- ZTS trades at 11.8x earnings versus 22.0x for the sector, which means the rerating case depends on proving the discount is too harsh.
- ZTS carries a beta of 0.74, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- ZTS is more relevant for investors who want some income support alongside price appreciation, not just pure growth exposure.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for ZTS come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for ZTS. Last refresh: Oct 8, 2026, 10:10 AM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Zoetis Inc. does
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care…
Employees
14,500
Industry
Drug Manufacturers - Specialty & Generic
Headquarters
Parsippany, United States
What analysts expect
ZTS carries a buy consensus from 14 analysts, with an average price target of $96.00 versus $71.55 today (+34.2%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
ZTS generated $9.53B in trailing revenue (-0.2% year over year), with a 27.7% net margin, and $2.02B of free cash flow, against $7.58B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $9.47B | $6.80B | $3.60B | $2.67B | $6.03 | $2.28B |
| 2024 | $9.26B | $6.54B | $3.39B | $2.49B | $5.47 | $2.30B |
| 2023 | $8.54B | $5.98B | $3.07B | $2.34B | $5.08 | $1.62B |
| 2022 | $8.08B | $5.63B | $2.93B | $2.11B | $4.51 | $1.33B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
ZTS is in 8 of the 30 ETFs we track. It weighs most in XLV: 0.47% of the fund, holding #42 of 62.
Famous investors who hold it
ZTS is in the latest 13F of 1 of the 15 famous investors we follow. Renaissance Technologies (Founded by Jim Simons) holds the most of it: 0.14% of the portfolio, position #157 of 2,931, as of Q2 2026.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
ZTS beside the healthcare names it is usually measured against.
What the chart is saying
In a downtrend, below both moving averages.
downtrend- Price is 3.4% below its 50-day average and 26.7% below its 200-day.
- RSI at 47 is neither stretched nor washed out.
- The nearest ceiling is $73.10 (+2.2%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is ZTS a good investment in 2026?
Zoetis Inc. trades at a P/E ratio of 11.8, with medium volatility (19.0% annualized). The stock is in a consolidation phase.
What is the risk level of ZTS?
Based on 30-day volatility of 19.0%, ZTS has MEDIUM risk. Beta of 0.74 indicates lower sensitivity to market movements than average.
Does ZTS pay dividends?
Yes, Zoetis Inc. has a dividend yield of 2.96%.
How far is ZTS from its all-time high?
Zoetis Inc. is 71.3% below its all-time high of $249.27, reached in December 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +46.6%, against +312.9% for the S&P 500 (SPY).
Which ETFs hold ZTS?
8 of the 30 popular ETFs we track hold Zoetis Inc.. The largest weights: XLV (0.47%), VIG (0.14%), VYM (0.13%), VTV (0.11%) and VOO (0.05%). Measured on each issuer's full holdings file, dated August 31 to September 24, 2026.
How much of VOO is ZTS?
0.05%, as of August 31, 2026: ZTS is holding #298 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.49 in Zoetis Inc..
Which famous investors own ZTS?
Renaissance Technologies (0.14% of Founded by Jim Simons's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for ZTS?
The average analyst price target for Zoetis Inc. (ZTS) is $96.00 based on 14 analyst estimates, about 34.2% above the current price of $71.55. The published range runs from $80.00 to $155.00.
How much revenue does ZTS generate?
Zoetis Inc. reported $9.53B in trailing twelve-month revenue. Revenue growth is running at -0.2% year over year. Net margin sits at 27.7%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare ZTS with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.